Cost-effectiveness of a novel lipoarabinomannan test for tuberculosis in patients with HIV

Krishna P Reddy, Claudia M Denkinger, Tobias Broger, Nicole C McCann, Ankur Gupta-Wright, Andrew D Kerkhoff, Pamela P Pei, Fatma M Shebl, Katherine L Fielding, Mark P Nicol, C Robert Horsburgh, Graeme Meintjes, Kenneth A Freedberg, Robin Wood, Rochelle P Walensky

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


BACKGROUND: A novel urine lipoarabinomannan assay (FujiLAM) has higher sensitivity and higher cost than the first-generation AlereLAM assay. We evaluated the cost-effectiveness of FujiLAM for tuberculosis testing among hospitalized people with HIV irrespective of symptoms.

METHODS: We used a microsimulation model to project clinical and economic outcomes of three testing strategies: 1) sputum Xpert MTB/RIF (Xpert); 2) sputum Xpert plus urine AlereLAM (Xpert+AlereLAM); 3) sputum Xpert plus urine FujiLAM (Xpert+FujiLAM). The modelled cohort matched that of a two-country clinical trial. We applied diagnostic yields from a retrospective study (yields for Xpert/Xpert+AlereLAM/Xpert+FujiLAM among those with CD4<200/µL: 33%/62%/70%; among those with CD4≥200/µL: 33%/35%/47%). Costs of Xpert/AlereLAM/FujiLAM were USD15/3/6 (South Africa) and USD25/3/6 (Malawi). Xpert+FujiLAM was considered cost-effective if its incremental cost-effectiveness ratio (USD/year-of-life saved) was <$940 (South Africa) and <$750 (Malawi). We varied key parameters in sensitivity analysis and performed a budget impact analysis of implementing FujiLAM countrywide.

RESULTS: Compared with Xpert+AlereLAM, Xpert+FujiLAM increased life expectancy by 0.2 years for those tested in South Africa and Malawi. Xpert+FujiLAM was cost-effective in both countries. Xpert+FujiLAM for all patients remained cost-effective compared with sequential testing and CD4-stratified testing strategies. FujiLAM use added 3.5% (South Africa) and 4.7% (Malawi) to five-year healthcare costs of tested patients, primarily reflecting ongoing HIV treatment costs among survivors.

CONCLUSIONS: FujiLAM with Xpert for tuberculosis testing in hospitalized people with HIV is likely to increase life expectancy and be cost-effective at the currently anticipated price in South Africa and Malawi. Additional studies should evaluate FujiLAM in clinical practice settings.

Original languageEnglish
Pages (from-to)e2077-e2085
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Issue number7
Early online date17 Nov 2020
Publication statusPublished - 1 Oct 2021


Dive into the research topics of 'Cost-effectiveness of a novel lipoarabinomannan test for tuberculosis in patients with HIV'. Together they form a unique fingerprint.

Cite this